

[1］Garber AJ，Duncan TG，Goodman AM，et al.Efficacy of metformin in type II diabetes：results of a double-blind，placebo-controlled，dose-response trial［J］.Am J Med，1997，103(6)：491-497. 

[2］Hoffmann J，Spengler M.Efficacy of 24-week monotherapy with acarbose，metformin，or placebo in dietary-treated NIDDM patients：the Essen-II Study［J］.Am J Med，1997，103(6)：483-490. 

[3］中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版). 

[4］Ji L，Li H，Guo X，et al.Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients：phase IV open-label trial［J］.PLoS One，2013，8(2)：e57222. 

[5］Esposito K，Chiodini P，Bellastella G，et al.Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes：systematic review of 218 randomized controlled trials with 78 945 patients［J］.Diabetes Obes Metab，2012，14(3)：228-233. 

[6］McIntosh B，Cameron C，Singh SR，et al.Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy：a systematic review and mixed-treatment comparison meta-analysis［J］.Open Med，2011，5(1)：e35-48. 

[7］Wulffele MG，Kooy A，Lehert P，et al.Combination of insulin and metformin in the treatment of type 2 diabetes［J］.Diabetes Care，2002，25(12)：2133-2140. 

[8］UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)［J］.Lancet，1998，352(9131)：854-865. 

[9］Garber AJ，Abrahamson MJ，Barzilay JI，et al.American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement-executive summary［J］.Endocr Pract，2013，19(3)：536-557. 

[10］Holman RR，Paul SK，Bethel MA，et al.10-year follow-up of intensive glucose control in type 2 diabetes［J］.N Engl J Med，2008，359(15)：1577-1589. 

[11］Wright AD，Cull CA，Macleod KM，et al.Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet，sulfonylurea，metformin，or insulin for 6 years from diagnosis：UKPDS73［J］.J Diabetes Complications，2006，20(6)：395-401. 

[12］Rachmani R，Slavachevski I，Levi Z，et al.Metformin in patients with type 2 diabetes mellitus：reconsideration of traditional contraindications［J］.Eur J Intern Med，2002，13(7)：428. 

[13］Cryer DR，Nicholas SP，Henry DH，et al.Comparative outcomes study of metformin intervention versus conventional approach the COSMIC approach study［J］.Diabetes Care，2005，28(3)：539-543. 

[14］Klarenbach S，Cameron C，Singh S，et al.Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitusinadequately controlled on metformin［J］.CMAJ，2011，183(16)：E1213-1220. 

[15］Ito H，Ishida H，Takeuchi Y，et al.Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus［J］.Nutr Metab (Lond)，2010，7: 83. 

[16］Donnelly LA，Doney AS，Hattersley AT，et al.The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes［J］.Diabet Med，2006，23(2): 128-133. 

[17］Ong CR，Molyneaux LM，Constantino MI，et al.Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes［J］.Diabetes Care，2006，29(11): 2361-2364. 

[18］American Diabetes Association.Standards of medical care in diabetes 2014［J］.Diabetes Care，2014，37 (Suppl 1): S14-80. 

[19］International Diabetes Federation.Global guideline for type 2 diabetes，2012. 

[20］Li CL，Pan CY，Lu JM，et al.Effect of metformin on patients with impaired glucose tolerance［J］.Diabet Med，1999，16：477-481. 

[21］Knowler WC，Barrett-Connor E，Fowler SE，et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin［J］.N Engl J Med，2002，346(6)：393-403. 

[22］Ramachandran A，Snehalatha C，Mary S，et al.shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)［J］.Diabetologia，2006，49(2)：289-297. 

[23］Diabetes Prevention Program Research Group，Knowler WC，Fowler SE，et al.10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study［J］.Lancet，2009，374(9702)：1677-1686. 

[24］Foretz M，Hebrard S，Leclerc J，et al.Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state［J］.J Clin Invest，2010，120(7)：2355-2369. 

[25］Sarabia V，Lam L，Burdett E，et al.Glucose transport in human skeletal muscle cells in culture.Stimulation by insulin and metformin［J］.J Clin Invest，1992，90(4)：1386-1395. 

[26］Zhou G，Myers R，Li Y，et al.Role of AMP-activated protein kinase in mechanism of metformin action［J］.J Clin Invest，2001，108(8)：1167-1174. 

[27］Masini M1，Anello M2，Bugliani M3，et al.Prevention by metformin of alterations induced by chronic exposure to high glucose in human islet beta cells is associated with preserved ATP/ADP ratio［J］.Diabetes Res Clin Pract，2014，104(1)：163-170. 

[28］Lupi R1，Del Guerra S，Tellini C，et al.The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose［J］.Eur J Pharmacol.1999，364(2-3)：205-209. 

[29］Cho YM，Kieffer TJ.New aspects of an old drug：metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitizer［J］.Diabetologia，2011，54(2)：219-222. 

[30］潘长玉主译.Joslin糖尿病学［M］.第14版.北京：人民卫生出版社，2007. 

[31］Metformin：a practical guide to optimising outcomes Round-table discussion held in Edinburgh，December 2007［J］.Br J Diabetes Vasc Dis，2008，8：153-155. 

[32］中美上海施贵宝制药有限公司.格华止说明书. 

[33］Schwartz S，Fonseca V，Berner B，et al.Efficacy，tolerability，and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes［J］.Diabetes Care，2006，29(4)：759-764. 

[34］Yang W，Liu J，Shan Z，et al.Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes：an open-label，non-inferiority randomised trial［J］.Lancet Diabetes Endocrinol，2014，2(1)：46-55. 

[36］Blonde L，Rosenstock J，Mooradian AD，et al.Glyburide/ metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy［J］.Diabetes Obes Metab，2002，4(6)：368-375. 

[37］Goldstein BJ，Pans M，Rubin CJ.Multicenter，randomized，double-masked，parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea［J］.Clin Ther，2003，25(3)：890-903. 

[40］Fonseca V，Rosenstock J，Patwardhan R，et al.Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus：a randomized controlled trial［J］.JAMA，2000，283(13)：1695-1702. 

[41］Bailey CJ，Bagdonas A，Rubes J，et al.Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus：a 24-week，multicenter，randomized，double-blind，parallel-group study［J］.Clin Ther，2005，27(10)：1548-1561. 

[42］Wang W，Bu R，Su Q，et al.Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy［J］.Expert Opin Pharmacother，2011，12(18)：2791-2799. 

[43］Ristic S，Collober-Maugeais C，Pecher E，et al.Comparison of nateglinide and gliclazide in combination with metformin，for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone［J］.Diabet Med，2006，23(7)：757-762. 

[44］Schwarz SL，Gerich JE，Marcellari A，et al.Nateglinide，alone or in combination with metformin，is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes［J］.Diabetes Obes Metab，2008，10(8)：652-660. 

[45］Cho YM，Koo BK，Son HY，et al.Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus［J］.J Diabetes Invest，2010，1:143-148.

[46］Phillips P，Karrasch J，Scott R，et al.Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin［J］.Diabetes Care，2003，26(2)：269-273. 

[47］Pratley RE，Fleck P，Wilson C.Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes：a randomized，double-blind，6-month study［J］.Diabetes Obes Metab，2014，16(7)：613-621. 

[48］Wu D，Li L，Liu C.Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus：a meta-analysis［J］.Diabetes Obes Metab，2014，16(1)：30-37. 

[49］Matthews DR，Dejager S，Ahren B，et al.Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglyceamic risk compared with glimepiride，with no weight gain:result from a 2-year study［J］.Diabetes Obes Metab，2010，12:780-789. 

[50］Nauck M，Frid A，Hermansen K，et al.Long-term efficacy and safety comparison of liraglutide，glimepiride and placebo，all in combination with metformin in type 2 diabetes：2-year results from the LEAD-2 study［J］.Diabetes Obes Metab，2013，15(3)：204-212. 

[51］Yang W，Chen L，Ji Q，et al.Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China，South Korea and India：a 16-week，randomized，double-blind，active control trial［J］.Diabetes Obes Metab，2011，13(1)：81-88. 

[52］Derosa G，Cicero AF，Franzetti IG，et al.Effects of exenatide and metformin in combination on some adipocytokine levels：a comparison with metformin monotherapy［J］.Can J Physiol Pharmacol，2013，91(9)：724-732. 

[53］Strowig SM，Aviles-Santa ML，Raskin P.Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes［J］.Diabetes Care，2002，25(10)：1691-1698. 

[54］Kooy A，de Jager J，Lehert P，et al.Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus［J］.Arch Intern Med，2009，169(6)：616-625. 

[55］Liao L，Yang M，Qiu LL，et al.Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone［J］.Chin Med J (Engl)，2010，123(24)：3684-3688. 

[56］Giugliano D，Quatraro A，Consoli G，et al.Metformin for obese，insulin-treated diabetic patients：improvement in glycaemic control and reduction of metabolic risk factors［J］.Eur J Clin Pharmacol，1993，44(2)：107-112. 

[57］Strowig SM，Aviles-Santa ML，Raskin P.Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes［J］.Diabetes Care，2002，25:1691-1698. 

[58］Yki-Jarvinen H，Ryysy LNikkila K，et al.Cmparison of bedtime insulin regimens in patients with type 2 diabetes mellitus.A randomized，controlled trial［J］.Ann Intern Med，1999，130:389-396. 

[59］Kahn SE，Haffner SM，Heise MA，et al.Glycemic durability of rosiglitazone，metformin，or glyburide monotherapy［J］.N Engl J Med，2006，355:2427-2443. 

[60］Williams-Herman D，Johnson J，Teng R，et al.Efficacy and safety of sitagliptinand metforminas initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes［J］.Diabetes Obes Metab，2010，12:442-451. 

[61］Lund SS，Tarnow L，Astrup AS，et al.Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes［J］.Diabetes Obes Metab，2009，11(10)：966-977. 

[62］Lund SS，Tarnow L，Astrup AS，et al.Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control.A randomized study［J］.PLoS One，2008，3(10)：e3363. 

[63］中华医学会糖尿病学分会.中国1型糖尿病诊治指南［M］.北京：人民卫生出版社，2012. 

[64］Charbonnel B，Schernthaner G，Brunetti P，et a.Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes［J］.Diabetologia，2005，48(6)：1093-104. 

[65］Eurich DT，Weir DL，Majumdar SR，et al.Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure：systematic review of observational studies involving 34，000 patients［J］.Circ Heart Fail，2013，6(3)：395-402. 

[66］International Diabetes Federation.Managing older people with type 2 diabetes.Global guideline，2013. 

[67］中国老年学会老年医学会老年内分泌代谢专员委员会.老年糖尿病诊疗措施专家共识(2013年版)［J］.中华内科杂志，2014，53(3)：243-251. 

[68］田慧，李春霖，杨光，等.二甲双胍在老年2型糖尿病患者应用的安全性评估［J］.中华内科杂志，2008，47(11)：914-918. 

[69］杨光，李春霖，田慧，等.老年2型糖尿病患者使用二甲双胍后血乳酸水平的变化［J］.中国药物应用与监测，2008，5(2)：12-15. 

[70］全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估［J］.中华肾病杂志，2006，22(10)：589-595. 

[71］Copeland KC，Silverstein J，Moore KR，et al.Management of newly diagnosed type 2 Diabetes Mellitus (2型糖尿病) in children and adolescents［J］.Pediatrics，2013，131(2)：364-382. 

[72］中华医学会儿科学分会内分泌学组，中华医学会儿科学分会心血管学组，中华医学会儿科学分会儿童保健学组.中国儿童青少年代谢综合征定义和防治建议［J］.中华儿科杂志，2012，50(6)：420-422. 

[73］Nathan DM，Davidson MB，DeFronzo RA，et al.Impaired fasting glucose and impaired glucose tolerance：implications for care［J］.Diabetes Care，2007，30：753-759. 

[74］杨慧霞主编.妊娠合并糖尿病临床实践指南(第2版)［M］.北京：人民卫生出版社，2013. 

[75］Nawaz FH，Rizvi J.Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome［J］.Gynecol Obstet Invest，2010，69(3)：184-189. 

[76］Khattab S1，Mohsen IA，Aboul Foutouh I，et al.Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study［J］.Gynecol Endocrinol，2011，27(10)：789-793. 

[77］中国医师协会内分泌代谢科医师分会.２型糖尿病合并慢性肾脏病患者口服降糖药用药原则中国专家共识［J］.中国糖尿病杂志，2013，21(10)：865-870. 

[78］Owen RJ，Hiremath S，Myers A，et al.Consensus Guidelines for the Prevention of Contrast Induced Nephropathy.Canadian Association of Radiologists，2011.http：//www.car.ca/uploads/standards%20guidelines/20110617_en_prevention_cin.pdf. 

[79］Owen RJ，Hiremath S，Myers A，et al.Canadian Association of Radiologists Consensus Guidelines for the Prevention of Contrast-Induced Nephropathy：Update 2012［J］.Can Assoc Radiol J，2014，65(2)：96-105. 

[80］Stacul F，van der Molen AJ，Reimer P，et al.Contrast induced nephropathy：updated ESUR Contrast Media Safety Committee guidelines.Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)［J］.Eur Radiol，2011，21(12)：2527-2541. 

[81］Nathan DM，Buse JB，Davidson MB，et al.Management of hyperglycemia in type 2 diabetes：a consensus algorithm for the initiation and adjustment of therapy：a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes［J］.Diabetologia，2006，49(8)：1711-1721. 

[82］Pflipsen MC，Oh RC，Saguil A，et al.The prevalence of vitamin B(12) deficiency in patients with type 2 diabetes：a cross-sectional study［J］.J Am Board Fam Med，2009，22(5)：528-534. 

[83］Hermann L，Nilsson B，Wettre S，et al.Vitamin status of patients treated with metformin：a cross-sectional cohort study［J］.British Journal of Diabetes ＆Vascular Disease，2004，4：401. 

[84］de Jager J，Kooy A，Le hert P，et al.Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency：randomised placebo controlled trial［J］.BMJ，2010，340：c2181. 

[85］Kos E，Liszek MJ，Emanuele MA，et al.Effect of metformin therapy on vitamin D and vitamin B levels in patients with type 2 diabetes mellitus［J］.Endocr Pract，，2012，18(2)：179-184. 

[86］李萌，纪立农.二甲双胍在T2DM患者中的安全性［J］.中国糖尿病杂志，2014，22:289-292. 

[87］Muskiet MH，Smits MM，Morsink LM，et al.The gut-renal axis：do incretin-based agents confer renoprotection in diabetes?［J］.Nat Rev Nephrol，2014，10(2)：88-103. 

[88］Salpeter SR，Greyber E，Pasternak GA，et al.Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus［J］.Cochrane Database Syst Rev，2010，4：CD002967. 

[89］Roussel R，Travert F，Pasquet B，et al.Metformin use and mortality among patients with diabetes and atherothrombosisv.Arch Intern Med，2010，170(21)：1892-1899. 

[90］Hong J，Zhang Y，Lai S，et al.Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.Diabetes Care，2013，36(5)：1304-1311. 

[91］De Jager J，Kooy A，Lehert P，et al.Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus：a randomized，placebo-controlled trial［J］.J Intern Med，2005，257(1)：100-109. 

[92］Mather KJ，Verma S，Anderson TJ.Improved endothelial function with metformin in type 2 diabetes mellitus［J］.J Am Coll Cardiol，2001，37(5)：1344-1350. 

[93］Ma J，Liu LY，Wu PH，et al.Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China［J］.J Diabetes Res，2014，2014：294017. 

[94］Wang H，Ni Y，Yang S，et al.The effects of gliclazide，metformin，and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus.Curr Ther Res Clin Exp，2013，75：88-92. 

[95］Sin HY，Kim JY，Jung KH.Total cholesterol，high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin［J］.Arch Pharm Res，2011，34(1)：99-107. 

[96］中华医学会肝病学分会脂肪肝和酒精性肝病学组.中国非酒精性脂肪性肝病诊疗指南(2010年修订版)［J］.中国医学前沿杂志(电子版)，2012，4(7)：4-10. 

[97］Fruci B，Giuliano S，Mazza A，et al.Nonalcoholic fatty liver：a possible new target for type 2 diabetes prevention and treatment［J］.Int J Mol Sci，2013，14：22933-22966. 

[98］Endocrine Society，Legro RS，Arslanian SA，Ehrmann DA，et al.Diagnosis and treatment of polycystic ovary syndrome:an Endocrine Society clinical practice guideline.J Clin Endocrinol Metab，2013，984565-4592. 

[99］Tang T，Lord JM，Norman RJ，et al.Insulin-sensitising drugs (metformin，rosiglitazone，pioglitazone，D-chiro-inositol) for womenwith polycystic ovary syndrome，oligo amenorrhoea and subfertility［J］.Cochrane Database Syst Rev，2010，CD003053. 

[100］Aghahosseini M，Aleyaseen A，Safdarian L，et al.Metformin 2，500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight，hormones，and lipid profile［J］.Arch Gynecol Obstet，2010，282(6)：691-694. 

[101］Jalving M，Gietema JA，Lefrandt JD，et al.Metformin：Taking away the candy for cancer?［J］.Eur J Cancer，2010，46：2369-2380. 

[102］Musi N，Hirshman MF，Nygren J，et al.Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes［J］.Diabetes2002，51:2074-2081. 

[103］Fryer LG，Parbu-Patel A，Carling D.Theanti-diabetc drugs rosiglitaszone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways［J］.J Biol Chem，2002，277:25226-25232. 

[104］Hawlay SA，Gadalla AE，Olsen GS，et al.The antidiabetic drug metfomin activates the AMP-activited protein kinase cascade via an adenine nucleotide-independent mechanism［J］.Diabetes，2002，51:2420-2425. 

[105］Luo Z，Saha AK，Xiang X，et al.AMPK，the metabolic syndrome and cancer［J］.Trends Pharmacol Sci，2005，26:69-76. 

[106］Evans JM，Donnelly LA，Emslie-Smith AM，et al.Metformin and reduced risk of cancer in diabetic patients［J］.Br Med J，2005，330(7503)：1304-1305. 